A practical reference on receptor agonist: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-02-26. Anything still debated is marked as such rather than presented as settled.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
Serum protein binding dominates the pharmacokinetic profile. The attached chain associates strongly with albumin, shielding the peptide from enzymatic attack and slowing filtration by the kidney. This interaction extends the circulation half-life to roughly one week in humans, which supports weekly administration intervals. An oral version pairs the peptide with an absorption enhancer that transiently alters gastric epithelium, permitting limited uptake; bioavailability by that route is substantially lower than by injection.
Semaglutide belongs to the glucagon-like peptide-1 receptor agonist class, a group of synthetic peptides that imitate an incretin hormone released by intestinal L cells after food intake. Native GLP-1 circulates for only a few minutes because dipeptidyl peptidase-4 cleaves it rapidly. The hormone acts on pancreatic islets, the gastrointestinal tract, and several brain regions. Because the natural peptide is short-lived, development work concentrated on analogues that keep receptor activity while resisting enzymatic breakdown and renal clearance.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Acylated GLP-1 receptor agonist | 31-residue synthetic peptide |
| Molecular formula | C187H291N45O59 | established for the free peptide |
| Appearance | White to off-white powder | as supplied before formulation |
| Solubility | Freely soluble in water | aqueous buffers near neutral pH |
| Typical storage | 2 to 8 degrees Celsius, protected from light | powder and solution forms differ in shelf life |
Identity and purity are usually assessed by reverse-phase high-performance liquid chromatography coupled to mass spectrometry. Retention time and observed mass are compared against a reference standard run under identical conditions. Impurity profiles reveal deamidation products, oxidized methionine variants, and truncated fragments that arise during synthesis or storage. Peptide mapping through enzymatic digestion confirms the primary sequence, while amino acid analysis offers an independent check on overall composition.
Stability studies examine how temperature, pH, and moisture influence degradation rates over time. In aqueous solution, hydrolysis and deamidation accelerate as pH moves away from mildly acidic conditions. Light exposure and residual metal ions can also trigger oxidation of susceptible residues. Accelerated aging at elevated temperature is used to estimate shelf life, though extrapolation to room temperature carries uncertainty because individual degradation pathways do not always scale predictably.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Hydrogen peroxide (H2O2) is a nonplanar molecule with (twisted) C2 symmetry; this was first shown by Paul-Antoine Giguère in 1950 using infrared spectroscopy. Although the O−O bond is a single bond, the molecule has a relatively high energy barrier of 386 cm−1 (4.62 kJ/mol) for rotation between enantiomers via the anti configuration, and 2460 cm−1 (29.4 kJ/mol) via the eclipsed configuration. These barriers are proposed to be due to repulsion between the lone pairs of the adjacent oxygen atoms and dipolar effects between the two O–H bonds. For comparison, the rotational barrier for ethane is 1040 cm−1 (12.4 kJ/mol). The approximately 100° dihedral angle between the two O–H bonds makes the molecule chiral. It is the smallest and simplest molecule to exhibit enantiomerism. It has been proposed that the enantiospecific interactions of one rather than the other may have led to amplification of one enantiomeric form of ribonucleic acids and therefore an origin of homochirality in an RNA world. The molecular structures of gaseous and crystalline H2O2 are significantly different. This difference is attributed to the effects of hydrogen bonding, which is absent in the gaseous state. Crystals of H2O2 are tetragonal with the space group D44 or P41212.
Lactose, maltose and sucrose are disaccharides, also called "compound sugars". They share the formula C12H22O11. They are formed by the condensation of two monosaccharide molecules with the expulsion of a molecule of water.
=== January === 1 January – A visit by Thor the Walrus to Scarborough harbour, North Yorkshire overnight on New Year's Eve results in the town's New Year fireworks celebrations being cancelled to let the walrus rest for his journey to the Arctic. He was previously spotted at Pagham Harbour, Calshot, Hampshire in December 2022. 2 January – Thor the Walrus makes an appearance in Blyth, Northumberland. 7 January – Prime Minister Rishi Sunak holds talks with health leaders in England to discuss pressures facing the National Health Service. 8 January – The government confirms plans to ban single-use items such as plastic cutlery, plates, and trays in England, with the ban subsequently announced to take effect from October. 13 January Dennis McGrory, aged 75, is sentenced to life imprisonment for the 1975 murder of 15-year-old Jacqueline Montgomery following a trial at Huntingdon Crown Court. His conviction is the oldest murder case in England and Wales to involve the rule of double jeopardy. Following a trial at Hove Crown Court, Mark Brown, 41, of St Leonards-on-Sea, East Sussex, is given two life sentences for the 2021 murders of Alexandra Morgan and Leah Ware. 14 January – Four women and two children are injured in a drive-by mass shooting close to a Catholic church in Euston Road, Euston, Central London. A 22-year-old man is arrested two days later on suspicion of attempted murder.
Sources: en.wikipedia.org
The Dietary Reference Intake for sodium is 1.5 grams per day, but most people in the United States consume more than 2.3 grams per day, the minimum amount that promotes hypertension; this in turn causes 7.6 million premature deaths worldwide. Potassium is the major cation (positive ion) inside animal cells, while sodium is the major cation outside animal cells. The concentration differences of these charged particles causes a difference in electric potential between the inside and outside of cells, known as the membrane potential. The balance between potassium and sodium is maintained by ion transporter proteins in the cell membrane. The cell membrane potential created by potassium and sodium ions allows the cell to generate an action potential—a "spike" of electrical discharge. The ability of cells to produce electrical discharge is critical for body functions such as neurotransmission, muscle contraction, and heart function. Disruption of this balance may thus be fatal: for example, ingestion of large amounts of potassium compounds can lead to hyperkalemia strongly influencing the cardiovascular system. Potassium chloride is used in the United States for lethal injection executions.
Numerous artists and writers living in France in the late 19th and early 20th centuries were noted absinthe drinkers and featured absinthe in their work. Some of these included Édouard Manet, Guy de Maupassant, Paul Verlaine, Amedeo Modigliani, Edgar Degas, Henri de Toulouse-Lautrec, Vincent van Gogh, Oscar Wilde, Arthur Rimbaud, and Émile Zola. Many other renowned artists and writers similarly drew from this cultural well, including Aleister Crowley, Ernest Hemingway, Pablo Picasso, August Strindberg, and Erik Satie. The aura of illicitness and mystery surrounding absinthe has played into literature, movies, music, and television, where it is often portrayed as a mysterious, addictive, and mind-altering drink. Marie Corelli's Wormwood: A Drama of Paris (1890) was a popular novel about a Frenchman driven to murder and ruin after being introduced to absinthe. Intended as a morality tale on the dangers of the drink, it was speculated to have contributed to subsequent bans of absinthe in Europe and the United States. Some of the earliest film references include The Hasher's Delirium (1910) by Émile Cohl, an early pioneer in the art of animation, as well as two different silent films, each titled Absinthe, from 1913 and 1914 respectively. More recently, it served as the title of a 2018 song by the indie group I Don't Know How But They Found Me.
== Mucosa-associated lymphoid tissue == Both innate and acquired responses are important in ocular defenses. One major pathway in which both are incorporated is the network of lymphoid cells that form the mucosa-associated lymphoid tissue (MALT). MALT is a major component in all mucosal organs, including the respiratory, genital, digestive, and ocular tracts. Regulated migrations of immune cells are known to occur between these mucosal organs. However, the role of MALT in human ocular defenses is not fully understood. However, it is known that the lacrimal glands and the conjunctiva contribute to ocular defenses via secretion of both immunoglobulins and lymphoid tissues. The latter is understood to be organized into clumps of lymphoid follicles as well as diffuse lymphoid tissues. In the follicular form of MALT, antigens are taken up by the follicles and presented to lymphocytes by antigen presenting cells. This leads to activation of B and T cells that carry out the immune reaction. Diffuse lymphoid tissues, on the other hand, is composed mainly of interspersed effector cells. Generally, both pathways lead to activation and migration of immune cells within the mucosal tissues, including the conjunctiva.
Brimonidine is an α2 agonist medication used to treat open-angle glaucoma, ocular hypertension, and rosacea. In rosacea it improves the redness. It is used as eye drops or applied to the skin. It is also available in the fixed-dose combination medication brimonidine/timolol along with timolol maleate. Common side effects when used in the eyes include itchiness, redness, and a dry mouth. Common side effects when used on the skin include redness, burning, and headaches. More significant side effects may include allergic reactions and low blood pressure. Use in pregnancy appears to be safe. When applied to the eye it works by decreasing the amount of aqueous humor made while increasing the amount that drains from the eye. When applied to the skin it works by causing blood vessels to contract. Brimonidine was patented in 1972 and came into medical use in 1996. It is available as a generic medication. In 2023, it was the 213th most commonly prescribed medication in the United States, with more than 2 million prescriptions.
Sources: en.wikipedia.org
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and neutral endopeptidases. Semaglutide carries a non-natural amino acid at position eight that blocks that cleavage, and a fatty diacid side chain that binds albumin. The result is a much longer duration of action than the native hormone.
The fatty diacid chain associates strongly with serum albumin, which keeps the peptide in circulation and shields it from rapid renal clearance. Bound peptide is released gradually, producing a sustained receptor signal. This mechanism also reduces the peak-to-trough variation seen with shorter-acting analogues.
The balance between peripheral receptor activation and signalling in the central nervous system is not fully resolved. The extent to which slowed gastric emptying accounts for reduced energy intake, compared with direct effects on appetite circuits, is debated. Long-term effects on lean mass and on tissues outside the gut and brain are still under study.
It is a synthetic peptide of 31 amino acids, built to resemble the natural incretin hormone GLP-1. Because of its size and composition it is handled analytically like other therapeutic peptides, using chromatographic and mass spectrometric methods rather than the techniques typical of small organic drugs.